论文部分内容阅读
由中国中医药学会武汉分会组织召开的敖东药业集团新产品“益血生”、“利脑心”学木报告会已在汉召开.“益血生”在中医理论指导下,经多年临床验证而定方,经多项药理实验的结果证明无毒副作用,是治疗缺铁性贫血、再生障碍性贫血、营养不良性贫血、原发性血小板减少性紫癜、急性白血病等症的首选用药.经临床304例各类贫血患者的观察治疗,其总有效率为92.4%,荣获部优质新产品奖.“利脑心”具有增加冠脉血流量、降低血脂含量、增强人体内纤维蛋白溶解系统活性及抗凝作用.经临床342例观察,按全国冠心病座谈会标准,心绞痛疗效80.7%,心电图验证疗效40.1%.适用于冠心病、心绞痛、心肌梗塞、脑动脉硬化、脑血栓等缺血性心脑血管疾病,长期服用可预防心脑血管疾病.与会专家充分肯定了以上两种中成药的治疗作用,并推荐广泛用于临床.
The report of the “Yi Xue Sheng” and “Li Nao Xin” learning wood products of the Qidong Pharmaceutical Group, organized by the Chinese Society of Chinese Medicine in Wuhan, has been held in Han. “Yi Xue Sheng” has been under the guidance of traditional Chinese medicine theory for many years. Dingfang has been clinically tested and proved to be non-toxic and side effects through the results of several pharmacological experiments. It is the first choice for the treatment of iron deficiency anemia, aplastic anemia, malnutrition anemia, idiopathic thrombocytopenic purpura, and acute leukemia. Clinical observation and treatment of 304 patients with various kinds of anemia, the total effective rate was 92.4%, won the Ministry of high quality new product award. “Li brain heart” has increased coronary blood flow, lower blood lipid levels, enhance the body’s fibrinolysis System activity and anticoagulant effect. Clinically observed 342 cases, according to the national standards of coronary heart disease forum, 80.7% angina effect, ECG validation 40.1%. Applicable to coronary heart disease, angina pectoris, myocardial infarction, cerebral arteriosclerosis, cerebral thrombosis and other defects Bloody cardiovascular and cerebrovascular diseases, long-term use can prevent cardiovascular and cerebrovascular diseases. Experts at the meeting fully affirmed the therapeutic effects of the above two proprietary Chinese medicines and recommended them for clinical use.